April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Clinical Outcomes of Ocular Inflammatory Disease Patients Treated With Cyclosporine-A as a Single Immunomodulatory Agent
R. Kacmaz; J. H. Kempen; C. Newcomb; R. B. Nussenblatt; J. T. Rosenbaum; E. B. Suhler; J. E. Thorne; D. A. Jabs; G. A. Levy-Clarke; C. Foster
Author Affiliations & Notes
  • R. Kacmaz
    Mount Sinai School of Medicine, New York, New York
  • J. H. Kempen
    Ocular Inflammation Service, Scheie Eye Institute, Philadelphia, Pennsylvania
  • C. Newcomb
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania
  • R. B. Nussenblatt
    Laboratory of Immunology, National Eye Institute, Bethesda, Maryland
  • J. T. Rosenbaum
    Department of Ophthalmology, Departments of Ophthalmology and Medicine,
    Oregon Health & Science University, Portland, Oregon
  • E. B. Suhler
    Department of Ophthalmology,
    Oregon Health & Science University, Portland, Oregon
  • J. E. Thorne
    Departments of Ophthalmology and Epidemiology, The Johns Hopkins University, Baltimore, Maryland
  • D. A. Jabs
    Department of Ophthalmology, Departments of Ophthalmology and Medicine,
    Mount Sinai School of Medicine, New York, New York
  • G. A. Levy-Clarke
    St. Luke’s Cataract and Laser Institute, Tarpon Springs, Florida
  • C. Foster
    Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts
  • Footnotes
    Commercial Relationships  R. Kacmaz, None; J.H. Kempen, None; C. Newcomb, None; R.B. Nussenblatt, None; J.T. Rosenbaum, received $10,000 for consulting fees or paid advisory boards for both Novartis and Abbott Laboratories, and having a research grant pending from Abbott Laboratories, C; E.B. Suhler, received a research grant from Abbott Laboratories, F; J.E. Thorne, None; D.A. Jabs, received $10,000 for consulting fees or paid advisory boards for Novartis., C; G.A. Levy-Clarke, None; C. Foster, None.
  • Footnotes
    Support  National Eye Institute Grant EY014943, Paul and Evanina Mackall Foundation and Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2699. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Clinical Outcomes of Ocular Inflammatory Disease Patients Treated With Cyclosporine-A as a Single Immunomodulatory Agent
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      R. Kacmaz, J. H. Kempen, C. Newcomb, R. B. Nussenblatt, J. T. Rosenbaum, E. B. Suhler, J. E. Thorne, D. A. Jabs, G. A. Levy-Clarke, C. Foster; Clinical Outcomes of Ocular Inflammatory Disease Patients Treated With Cyclosporine-A as a Single Immunomodulatory Agent. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2699.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate the clinical outcomes of cyclosporine-A used as a single immunomodulatory agent for non-infectious ocular inflammation

Methods: : 444 consecutive patients with non-infectious ocular inflammation started on cyclosporine as a single immunomodulatory agent at five ocular inflammation subspecialty centers between 1979-2007 were included. Demographic and clinical characteristics, including dosage of cyclosporine-A and main outcome measures (control of inflammation, corticosteroid-sparing effects, incidence of and reason for discontinuation of therapy) were obtained for every eye of every patient at every visit by medical record review.

Results: : Of the 444 patients (819 eyes with ocular inflammation) observed to start cyclosporine-A monotherapy, 16.7%, 30.5%, 47.3%, 2.8%, and 2.6% respectively had anterior uveitis, intermediate uveitis,posterior/panuveitis, scleritis, and other forms of ocular inflammation. Within these groups, complete suppression of inflammation sustained for ≥28 days was achieved in ≤6 months in 29.2%, 29.2%, 23.7%, 62.3%, and 20% respectively. Corticosteroid-sparing success (controlled inflammation with prednisone ≤10 mg/day for ≥28 days) was achieved within 6 months among 27.5%, 18.7%, 14.1%, 52.8%, and 20% of the respective groups. However, results were substantially better using less stringent sucsess criteria. Cyclosporine-A was discontinued within ≤1 year by 210 (47%) patients. Side effects were the cause of discontinuation in 50 patients (11%), and typically were reversible with dose reduction/discontinuation.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • cyclosporine • uveitis-clinical/animal model 
© 2009, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept